On this website you can find more information about the Personalized Parkinson Project and other associated studies.
Personalized Parkinson Project
In 2017, the Radboudumc, in collaboration with the American company Verily Life Sciences, started the Personalized Parkinson Project (PPP). This is a large-scale study into the origin and course of Parkinson's disease. By extensively following a large group of people with Parkinson's disease for two years, we wanted to gain new knowledge and lay the foundation for personalized treatments.
PPP 'De Novo'
Because of the success of the PPP, a collaboration between the Radboudumc and the pharmaceutical company UCB (Union Chimique Belge) has started. This collaboration has led to a new study: PPP De Novo. This study differs from the PPP-study in that the focus is on collecting research data from people with parkinson's who are not yet taking parkinson's medication. The survey data will be used to develop a new measure to measure Parkinson's disease in a reliable and objective way.
Due to the succes of our previous studies, we continue to participate in new studies on Parkinson's disease and a-typical parkinsonism.
Update Personalized Parkinson ProjectRead the latest update on the Personalized Parkinson Project!20 October 2020
New study: PPP De NovoWe are proud to share we have recently started a large new add-on study called Personalized Parkinson Project De Novo!20 October 2020
Virtual Motor Exams with the Verily Study WatchIn May we enrolled Virtual Motor Examinations on the Verily Study Watch.20 October 2020